Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.78
$0.04(1.15%)
At close: 4:00 PM EST
$5.78
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$2.26 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.86M
Market Cap
$1.13B
Enterprise Value$1.21K
Total Cash (Recent Filing)$202.77M
Total Debt (Recent Filing)$30.11M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,579,429
30 Day Avg. Volume1,860,238
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Bulls Say, Bears Say
Bulls Say
Orphan-focused Pipeline (inhaled Molgramostim)Savara’s singular focus on inhaled molgramostim for aPAP targets a small, high-unmet-need orphan market. A narrowly targeted rare-disease program can yield durable pricing power, clearer regulatory pathways, and concentrated commercial efforts, improving long-term return potential if clinical success is achieved.
Manageable LeverageLow absolute debt and a sub-0.2 debt-to-equity ratio provide balance-sheet flexibility for a clinical-stage company. Manageable leverage reduces near-term solvency pressure and interest burden, allowing the firm to prioritize R&D and clinical milestones rather than servicing large debt loads while pursuing regulatory objectives.
Expanded Financing & Leadership ContinuityDoubling authorized shares and enlarging the incentive pool increase the company's ability to structure financings and employee awards, while promoting the COO to CFO/COO preserves institutional knowledge. Together these moves strengthen operational continuity and financing flexibility to support multi-stage clinical programs.
Bears Say
No Revenue; Widening Net LossesThe company has no commercial revenues and materially widening net losses, indicating prolonged dependence on external capital. Persistent loss generation erodes equity and means long-term viability hinges on successful trials or partnerships, making operational continuity contingent on future funding or product approval.
High, Accelerating Cash BurnOperating cash outflows have roughly doubled over two years, converting accounting losses into real cash depletion. Sustained, rising cash burn increases the frequency and size of future financing needs, raising dilution risk and constraining the company’s ability to fund trials or scale operations without external capital or partnerships.
Heightened Dilution Risk From Share ExpansionDoubling authorized shares and enlarging the equity award pool materially raises the potential for shareholder dilution via future issuances. Unless offset by substantial clinical or commercial progress, this structural increase in share capacity can reduce per-share economic recovery and amplify funding-related dilution over the medium term.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.26 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.13B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.015.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,927,220 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went up 3.74%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (93.19% Upside)
$11.17 (93.19% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.89%
12-Months-Change
Fundamentals
Return on Equity
-87.19%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.17
▲(93.19% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
7.48% Mutual Funds
0.14% Other Institutional Investors
77.76% Public Companies and
Individual Investors